Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to OSU, Tekmira, Nitto Denko, and More

Premium

Title: microRNA Expression in Human Peripheral Blood Microvesicles and Uses Thereof

Patent Number: 8,455,199

Filed: Sept. 12, 2008

Lead Inventor: Clay Marsh, Ohio State University

The invention, the patent’s abstract states, comprises “novel methods and compositions for the diagnosis, prognosis, and treatment of disorders by examining samples containing microvesicles and [miRNAs] therein.”


Title: Compositions and Methods for Silencing Genes Involved in Hemorrhagic Fever

Patent Number: 8,455,455

Filed: March 31, 2011

Lead Inventor: Marjorie Robbins, Protiva Biotherapeutics (Tekmira Pharmaceuticals)

The invention, the patent’s abstract states, provides “compositions comprising therapeutic nucleic acids such as interfering RNA that target Lassa virus or tissue factor gene expression, lipid particles comprising one or more of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles.”


Title: Method for Selecting siRNAs from a Plurality of siRNAs for Gene Silencing

Patent Number: 8,457,902

Filed: May 4, 2011

Lead Inventor: Aimee Jackson, Merck

The invention involves a “method for identifying siRNA target motifs in a transcript using a position-specific score matrix approach,” according to the patent’s abstract. “The invention also provides a method for identifying off-target genes of an siRNA using a position-specific score matrix approach … [as well as] a method for designing siRNAs with higher silencing efficacy and specificity … [and] a library of siRNAs comprising siRNAs with high silencing efficacy and specificity.”


Title: Agent for Treating Renal Fibrosis

Application Number: 20130136789

Filed: June 17, 2011

Lead Inventor: Yoshiro Niitsu, Nitto Denko

The invention, the patent application’s abstract states, “relates to a substance delivery carrier for extracellular matrix-producing cells in the kidney, the carrier including a retinoid as a targeting agent, an agent for treating renal fibrosis utilizing the carrier, a process for producing them, a production kit, [and] a method for treating renal fibrosis using the agent for treating renal fibrosis.”


Title: microRNA Expression Abnormalities in Pancreatic Endocrine and Acinar Tumors

Application Number: 20130137596

Filed: Dec. 27, 2012

Lead Inventor: Carlo Croce, Ohio State University

The invention comprises “novel methods and compositions for the diagnosis, prognosis, and treatment of pancreatic cancer,” the patent application’s abstract states. “The invention also provides methods of identifying anti-pancreatic cancer agent.”


Title: Double-stranded RNA-based Nanoparticles for Insect Gene Silencing

Application Number: 20130137747

Filed: May 31, 2012

Lead Inventor: Kun Yan Zhu, Kansas State University

The patent application, its abstract states, claims “insect RNAi via oral delivery … along with methods of silencing a target gene in a target insect using RNAi. … The nanoparticles comprise a polymer matrix and insect dsRNA … [which is made up of] … at least one sequence having a region of complementarity substantially complementary to at least a portion of an mRNA transcript of the target gene. Insect baits comprising the nanoparticles are also provided … [as are] methods of screening target gene functions … using the methods disclosed herein.”


Title: Double-stranded RNA Compounds to RhoA and Use Thereof

Application Number: 20130137750

Filed: June 23, 2011

Lead Inventor: Sharon Avkin-Nachum, Quark Pharmaceuticals

The invention relates to “compounds, pharmaceutical compositions comprising same, methods of use thereof, and kits for the down-regulation of RhoA gene,” the patent application’s abstract states. “The compounds, compositions, methods, and kits are useful in the treatment of subjects suffering from diseases or conditions and or symptoms associated with diseases or conditions in which RhoA expression has adverse consequences and for conferring neuroprotection.”


Title: RNA Interference-mediated Inhibition of Catenin, Beta 1 Gene Expression using Short Interfering Nucleic Acid

Application Number: 20130137752

Filed: Aug. 2, 2011

Lead Inventor: Duncan Brown, Merck

The invention relates to “compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases, and conditions that respond to the modulation of CTNNB1 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway,” the patent application’s abstract states. “Specifically, the invention relates to double-stranded nucleic acid molecules … capable of mediating or that mediate RNA interference against CTNNB1 gene expression.”

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.